251
|
Pozza G, Bosi E, Secchi A, Piatti PM, Touraine JL, Gelet A, Pontiroli AE, Dubernard JM, Traeger J. Metabolic control of type I (insulin dependent) diabetes after pancreas transplantation. BMJ : BRITISH MEDICAL JOURNAL 1985; 291:510-3. [PMID: 3928030 PMCID: PMC1416541 DOI: 10.1136/bmj.291.6494.510] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
A study was conducted of the circadian hormonal and metabolic patterns of 10 type I (insulin dependent) uraemic diabetic patients after pancreas and renal transplantation. A single 24 hour profile was obtained in each patient following as closely as possible his or her normal daily routine two to 15 months after transplantation. None of the patients were using insulin at the time of the study. Compared with a group of six normal subjects the transplant recipients had mildly raised blood glucose concentrations, hyperinsulinaemia between meals and at night, delayed postprandial insulin peaks, mild hyperketonaemia, and normal blood lactate and plasma glucagon concentrations. The findings showed that successful pancreas transplantation results in disappearance of the need for insulin and return to normal or near normal of the metabolic abnormalities of diabetes. The minor differences observed in comparison with normal hormonal and metabolic homoeostasis were probably due to intrinsic (reduced islet mass, denervation, peripheral hormone delivery) and environmental (immunosuppression, relatively impaired renal function) factors.
Collapse
|
252
|
Chiesa R, Vicari A, Mari G, Galimberti M, Di Carlo V, Pozza G. Use of stable prostacyclin analogue ZK 36 374 to treat severe lower limb ischaemia. Lancet 1985; 2:95-6. [PMID: 2409417 DOI: 10.1016/s0140-6736(85)90195-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
253
|
Pontiroli AE, De Pasqua A, Bonisolli L, Pozza G. Ageing and acetylator phenotype as determined by administration of sulphadimidine. Eur J Clin Pharmacol 1985; 28:485-6. [PMID: 4029255 DOI: 10.1007/bf00544374] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
254
|
Pontiroli AE, Alberetto M, Pozza G. Intranasal calcitonin and plasma calcium concentrations in normal subjects. BRITISH MEDICAL JOURNAL 1985; 290:1390-1. [PMID: 3922505 PMCID: PMC1415597 DOI: 10.1136/bmj.290.6479.1390] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
255
|
Pontiroli AE, Alberetto M, Pozza G. Metabolic effects of intranasally administered glucagon: comparison with intramuscular and intravenous injection. ACTA DIABETOLOGICA LATINA 1985; 22:103-10. [PMID: 3907228 DOI: 10.1007/bf02590783] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Intranasal administration of glucagon, 1 mg, plus sodium glycocholate 15 mg as a surfactant, raised blood glucose levels and plasma levels of immunoreactive glucagon (IRG) and immunoreactive insulin (IRI). Spray solutions were more effective than drops, and neither the surfactant alone nor glucagon alone had any effect. Blood glucose levels were similarly affected by intravenous glucagon, while intramuscular glucagon was slightly more effective. The highest IRG concentrations were reached after intravenous administration, while intramuscular injection of glucagon was accompanied by the highest IRI release. These data indicate that intranasal administration of glucagon exerts metabolic effects similar to intramuscular and intravenous administrations. Further studies are needed to improve bioavailability and efficacy of intranasally administered glucagon.
Collapse
|
256
|
Pontiroli AE, Alberetto M, Bertoletti A, Baio G, Pozza G. Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus. Horm Metab Res 1984; 16 Suppl 1:167-70. [PMID: 6398258 DOI: 10.1055/s-2007-1014925] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Indirect evidence suggests that sulfonylureas, in addition to stimulating insulin release, exert additional effects at extrapancreatic levels which are of value in the management of type 2 diabetes. In order to characterize in vivo some of these effects, insulin sensitivity was studied in 9 type 1 diabetics with no residual insulin secretory activity, during treatment with chlorpropamide (250 mg b.i.d. for 8 days) and with glipizide (5 mg t.i.d. for 8 days). Employing the glucose clamp technique with the aid of an artificial pancreas (Biostator), glucose disposal during insulin infusion (0.1 U/kg in 60 min) was calculated by the amount of glucose required to keep the blood glucose at preinfusion levels. Chlorpropamide and glipizide administration was accompanied by a significant increase of the amount of glucose required to clamp blood glucose levels, while serum (free) insulin levels were superimposable during the different clamping studies. In the absence of endogenous insulin release, these data strongly suggest that the two sulfonylureas employed enhance in vivo the peripheral sensitivity to insulin. Further studies are required to indicate a preferential site of action (liver, muscle, adipose tissue) of sulfonylureas.
Collapse
|
257
|
Vicari AM, Margonato A, Petrelli P, Vicedomini GG, Pozza G. Plasma beta-thromboglobulin concentration at rest and after physical exercise in complicated and uncomplicated diabetes mellitus. DIABETE & METABOLISME 1984; 10:235-8. [PMID: 6210218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Plasma beta-thromboglobulin concentration was measured in ten uncomplicated insulin-dependent diabetic subjects, in ten insulin-dependent patients with retinopathy and in ten age- and sex-matched healthy controls, both at rest and after cycloergometric exercise to exhaustion. Resting plasma beta-thromboglobulin was similar in the two patient groups and significantly higher than the control group. After exercising, plasma beta-thromboglobulin rose significantly only in the control group. Platelet hyperactivity is therefore present even in uncomplicated diabetes mellitus and is not influenced by the presence of complications. A chronic overstimulation of platelets could be responsible for the high basal plasma beta-thromboglobulin concentration in diabetes mellitus and for its abnormal behaviour after physical exercise.
Collapse
|
258
|
Pozza G, Secchi A, Bosi E, Pontiroli AE, Micossi P, Spotti D, Piatti PM, Gelet A, Touraine JL, Dubernard JM. Endocrine and metabolic profiles in insulin-dependent diabetics treated with continuous subcutaneous insulin infusion and pancreas transplantation: a comparison. Transplant Proc 1984; 16:1274-6. [PMID: 6385393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
259
|
Pontiroli AE, Mosca A, de Pasqua A, Alcini D, Pozza G. The fast acetylator phenotype in diabetes mellitus: abnormal prevalence and association with the ABO blood groups. Diabetologia 1984; 27:235-7. [PMID: 6489656 DOI: 10.1007/bf00273812] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The acetylator phenotype and ABO blood groups were evaluated in 55 normal subjects and in 156 diabetic patients [61 with Type 1 (insulin-dependent) diabetes and 95 with Type 2 (non-insulin-dependent) diabetes]. The prevalence of fast acetylators was significantly higher in the Type 1 diabetic patients (53%) than in the control subjects (29%). In the Type 2 diabetic patients the prevalence was 39%, and thus not significantly different from the control or Type 1 diabetic groups. In the Type 2 diabetic patients, but not in the control or in the Type 1 diabetic subjects, an association between the fast acetylator phenotype and the B blood group was found.
Collapse
|
260
|
Traeger J, Bosi E, Dubernard JM, Touraine JL, Piatti PM, Secchi A, Gelet A, Pozza G. Thirty months' experience with cyclosporin in human pancreatic transplantation. Diabetologia 1984; 27 Suppl:154-6. [PMID: 6383921 DOI: 10.1007/bf00275676] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Between September 1978 and December 1983, 33 simultaneous kidney plus pancreatic transplantations were performed in Type 1 (insulin-dependent) diabetic patients with uraemia at the Herriot Hospital, Lyon. In eight patients grafted before June 1981, immunosuppressive treatment consisted of azathioprine, steroids and a temporary course with anti-lymphocyte globulins (protocol A). Since June 1981, the immunosuppressive treatment has consisted of cyclosporin administered according to two protocols: from the day of transplantation with temporary anti-lymphocyte globulins with or without steroids (protocol B, seven patients), or after an initial course with protocol A, with or without steroids (protocol C, 18 patients). Only slight differences in patient and pancreatic graft survival between the three protocols were observed at 3, 6 and 12 months, while an improved survival rate for both patients and pancreatic grafts was observed in protocols B and C at 2 years. Moreover the incidence of pancreatic rejection as a cause of loss of pancreatic function seemed to be reduced under protocols B and C.
Collapse
|
261
|
Traeger J, Dubernard JM, Bosi E, Piatti PM, Gelet A, El Yafi S, Beutel H, Secchi A, Touraine JL, Pozza G. Patient selection and risk factors in organ transplantation in diabetics: experience with kidney and pancreas. Transplant Proc 1984; 16:577-82. [PMID: 6375024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
262
|
D'Angelo A, Micossi P, Mannucci PM, Garimberti B, Franchi F, Pozza G. Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes. Relationship to vascular complications. Eur J Clin Invest 1984; 14:83-6. [PMID: 6428908 DOI: 10.1111/j.1365-2362.1984.tb02092.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Platelet thromboxane B2 production was studied in forty-seven non-insulin-dependent diabetics by incubating platelets with increasing concentrations of arachidonic acid. In comparison with thirty-two healthy subjects, diabetics showed increased thromboxane B2 production at 0.7 mmol/l (mean: 236 pmol/10(8) platelets, SEM 201-277; v. 135, 105-174; P less than 0.05) and at 1.0 mmol/l (673, 613-739; v. 405, 377-486, P less than 0.01) but not at 0.5 mmol/l. Patients were subdivided according to the presence or absence of vascular complications. Patients without microangiopathy showed significantly greater thromboxane B2 production than healthy subjects at all the arachidonic-acid concentrations (P less than 0.02 or less). Patients with microangiopathy had platelet thromboxane production similar to that observed in healthy subjects at all the arachidonic-acid concentrations (P greater than 0.30) but significantly lower than that of non-microangiopathic patients at 0.5 (P less than 0.01) and at 0.7 mmol/l arachidonic acid (P less than 0.05). These results indicate that non-insulin-dependent diabetics have increased production of platelet thromboxane B2 only when they do not have microvascular complications.
Collapse
|
263
|
Secchi A, Hadj-Aissa A, Pozet N, Touraine JL, Pozza G, Dubernard JM, Traeger J. Renal glucose transport after kidney transplantation. Eur J Clin Invest 1984; 14:142-5. [PMID: 6428903 DOI: 10.1111/j.1365-2362.1984.tb02103.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Tubular maximal transport of glucose (TmG), plasma glucose threshold ( PGT ) and fractional maximal tubular reabsorption (TmG/GFR) were measured in fourteen kidney-grafted patients. Seven patients showed decreased PGT and normal or decreased TmG/GFR (type A or B renal glycosuria (RG) ), whereas seven other patients showed normal values. No difference was found between the two groups with respect to parameters of renal function and to clinical parameters characterizing kidney transplantation. The only difference observed between the two groups was the rate of decrease of plasma creatinine levels during the 1st week after transplantation: it was faster in the group without renal glycosuria. No difference was seen between the two groups of patients with respect to the number of rejection episodes occurred over the first 12 months.
Collapse
|
264
|
Micossi P, Spotti D, Pozza G. Artificial devices for continuous insulin administration: an outlook. Int J Artif Organs 1984; 7:1-6. [PMID: 6365796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
265
|
Pontiroli AE, Secchi A, Dabandi M, Alberetto M, Bosi E, Fantaguzzi S, Pozza G. Study of hypoglycemic patients by the glucose clamp technique using the artificial pancreas. J Clin Endocrinol Metab 1983; 57:1297-300. [PMID: 6313737 DOI: 10.1210/jcem-57-6-1297] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Using the artificial pancreas, blood glucose levels were maintained at 80 mg/dl in nine hypoglycemic patients (four with histologically proven insulinomas and five with nontumoral hypoglycemia) and in four normal subjects during a 24-h fast. The amount of glucose used, serum insulin levels, and glucose clearance were higher in patients with nontumoral hypoglycemia than in normal subjects and highest in the patients with an insulinoma. Surgical or pharmacological treatment resulted in normalization of all parameters. In contrast to the 72-h fast, the 24-h glucose clamp technique allowed the study of hypoglycemic patients without inducing hazardous hypoglycemia.
Collapse
|
266
|
Pozza G, Traeger J, Dubernard JM, Secchi A, Bosi E, Pontiroli AE. Cyclosporin and glucose tolerance in pancreas allotransplantation. Lancet 1983; 2:1080. [PMID: 6138620 DOI: 10.1016/s0140-6736(83)91062-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
267
|
Carenini A, Mosca A, Pozza G. Stable glycosylated hemoglobin as measured by a microcolumn method. Clin Chem 1983; 29:1687-8. [PMID: 6883681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
268
|
Bantle JP, Laine DC, Crapo P, Olefsky J, Steel J, Mitchell D, Prescott R, Munroe J, Douglas J, Ray T, Mansell K, Nathan DM, Pozza G, Spotti D, Sherwood M, Korhonen T. UPDATE of the Journals. DIABETES EDUCATOR 1983. [DOI: 10.1177/014572178300900316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
269
|
Carenini A, Mosca A, Pozza G. Stable glycosylated hemoglobin as measured by a microcolumn method. Clin Chem 1983. [DOI: 10.1093/clinchem/29.9.1687] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
270
|
|
271
|
Crepaldi G, Fedele D, Tiengo A, Battistin L, Negrin P, Pozza G, Canal N, Comi GC, Lenti G, Pagano G. Ganglioside treatment in diabetic peripheral neuropathy: a multicenter trial. ACTA DIABETOLOGICA LATINA 1983; 20:265-76. [PMID: 6356740 DOI: 10.1007/bf02581271] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Ganglioside treatment was evaluated with a multicenter, randomized, double-blind, controlled, cross-over vs placebo trial in 140 insulin-treated diabetic subjects with peripheral neuropathy. The patients entered the study when they showed an impairment in at least two of the electroneurographic parameters, and were assigned to two protocols according to the presence and severity of their neurological symptoms. Ninety-seven diabetic subjects with no or mild symptoms were assigned to protocol I, whereas 43 symptomatic patients were assigned to protocol II. the treatment periods lasted 6 weeks with an intermediate washout period of 4 weeks. The treatment consisted in the daily i.m. administration of 20 mg gangliosides or of placebo. Electroneurographic parameters were recorded at the beginning and at the end of each treatment period, whereas clinical and metabolic data (mean daily plasma glucose, glycosuria and glycosylated hemoglobin) were evaluated every three weeks in protocol I and every two weeks in protocol II. No change in the metabolic parameters was observed throughout the trial period. However, the treatment induced a statistically significant improvement of paresthesias (protocol II) and of some electrophysiological parameters; in particular, ganglioside treatment improved MCV of peroneal nerve (p less than 0.03) in patients of protocol I, MCV o ulnar nerve (p less than 0.002) and SCV of median nerve (p less than 0.06) in patients of protocol II. Furthermore, 22 subjects of protocol II showed a 'drug preference' while 10 preferred placebo and 9 had no preference. In conclusion, ganglioside treatment seems to have a positive effect on diabetic peripheral neuropathy, improving both some symptoms and some electrophysiological parameters.
Collapse
|
272
|
Micossi P, Raggi U, Dosio F, Scavini M, Bertin A, Pozza G. Open-loop device Microjet MC 2 improves unstable diabetes, lowers the daily insulin requirement and reduces the excursions of plasma free insulin levels: comparison with a traditional intensive treatment. J Endocrinol Invest 1983; 6:189-94. [PMID: 6352793 DOI: 10.1007/bf03350606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
273
|
Secchi A, Pontiroli AE, Traeger J, Dubernard JM, Touraine JL, Ruitton A, Blanc N, Pozza G. A method for early detection of graft failure in pancreas transplantation. Transplantation 1983; 35:344-8. [PMID: 6340290 DOI: 10.1097/00007890-198304000-00016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Pancreatic transplantation is intended to normalize carbohydrate metabolism in insulin-dependent diabetics by restoring endogenous insulin release, and it is usually performed together with kidney transplantation in patients with end-stage renal failure. A major problem in these patients is the daily control of the grafted pancreas because traditional measurements do not appear to be adequate to evaluate pancreatic function. Aiming at early detection of graft failure, we have analyzed in 8 such patients and in 20 nondiabetic kidney-grafted patients (a control group) the following variables: 24-hr glycosuria (absolute values, or values after natural logarithmic transformation) and 24-hr urinary C-peptide excretion (corrected for 24-hr urinary creatinine). These measurements, considered alone, did not detect pancreatic graft failure; for instance, glycosuria can depend on immunosuppressive steroid treatment, and it was often found even in the control group. On the contrary, the ratio Ln 24-hr glycosuria: 24-hr urinary C-peptide varied from 0.00 to 0.18 in the control group and in normally working pancreatic grafts; when the pancreatic grafts failed, however, as confirmed by arteriographic evidence, histologic findings, or dynamic endocrine tests, this ratio rose far higher than 0.18, reaching values as high as 12.2. Use of this ratio provides a simple technique for daily evaluation of pancreatic graft function and for early detection of graft failure.
Collapse
|
274
|
Pozza G, Traeger J, Dubernard JM, Secchi A, Pontiroli AE, Bosi E, Malik MC, Ruitton A, Blanc N. Endocrine responses of type 1 (insulin-dependent) diabetic patients following successful pancreas transplantation. Diabetologia 1983; 24:244-8. [PMID: 6134651 DOI: 10.1007/bf00282707] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The aim of the present study was to evaluate the insulin and glucagon responses to various stimuli in patients following pancreatic transplantation. Four Type 1 (insulin-dependent) diabetic patients with end-stage renal failure who had received a cadaveric segmental, neoprene-injected, pancreas transplant, in association with kidney transplantation, were investigated. Free-insulin, pancreatic glucagon, and growth hormone concentrations were measured after both oral and intravenous glucose tolerance tests, and following tolbutamide, arginine and arginine plus somatostatin infusions. Tests were performed 1 month (three cases) and 30 months (one case) after surgery, when no insulin administration was required. Four non-diabetic kidney grafted patients, matched for duration of graft survival and immunosuppressive treatment (steroids, azathioprine and anti-lymphocyte-globulins), served as control subjects. Impaired glucose tolerance was present in all diabetic and control patients. This was possibly related to immunosuppressive treatment. In comparison with control subjects, insulin release was normal in response to arginine and tolbutamide but was reduced in response to oral and intravenous glucose, while glucagon and growth hormone release were similar in both groups. Somatostatin was less effective in diabetic patients than in control subjects in suppressing insulin and glucagon release.
Collapse
|
275
|
Pontiroli AE, De Pasqua A, Colombo R, Ricordi C, Pozza G. Characterization of the chlorpropamide-alcohol-flush in patients with type 1 and type 2 diabetes. ACTA DIABETOLOGICA LATINA 1983; 20:117-23. [PMID: 6880563 DOI: 10.1007/bf02624912] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The aim of the present paper was to evaluate the prevalence of the chlorpropamide-alcohol-flush (CPAF) in patients with type 2 and with type 1 diabetes. Ninety-seven patients with type 2 diabetes and 33 with type 1 diabetes drank 40 ml vermouth 12 h after placebo and again 12 h after 1 tablet of chlorpropamide (250 mg) or 12 h after the last of repeated administrations of chlorpropamide (250 mg b.i.d. for 2 days). Skin temperature was recorded in all patients by a thermocouple probe connected to the left cheek. In 47 patients serum concentrations of chlorpropamide and of its metabolite CBSU were also determined. The prevalence of CPAF was similar in type 1 and type 2 diabetes, was greater in women than in men, and was significantly greater after repeated administrations than after one single administration of chlorpropamide. The increase of skin temperature during a 30-min period was significantly higher in patients with CPAF than in patients without CPAF. Serum concentrations of chlorpropamide and of its metabolite CBSU were more elevated after 4 than after 1 tablet of chlorpropamide, but were not significantly different in patients with and without CPAF. These data indicate that both genetic factors and the amount of chlorpropamide used affect the appearance of CPAF. To assess the possible role of serotonin and of dopamine in the CPAF, some patients with CPAF were tested again after treatment with metergoline, an antiserotonin agent, or with bromocriptine, a dopamine-agonist. Neither drug influenced the CPAF, indicating that the two neurotransmitters are not involved in the CPAF.
Collapse
|